Floatz logo

Tislelizumab

Esophageal Adenocarcinoma

BeOne Medicinesmonoclonal_antibodyPhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
73/ 100

Competitive context

47 Active assets in the Esophageal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
I-Mab Biopharma US Limited
Phase 3BB
Capecitabine
I-Mab Biopharma US Limited
Phase 3B
Cetuximab
BeOne Medicines
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3B
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 3B

View all 50 →

Same molecule, other indications

Tislelizumab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
Hepatic Metastasis of Pancreatic CancerDormant
BB
Indicative ·
69 / 100
View asset →
Primary Peritoneal Cavity CancerDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →